View Filter All NewsPress Release Years All Years202120202019201820172016201520142013201220112010 Apply Press Release | December 01, 2021 Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis READ MORE Press Release | November 19, 2021 Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene READ MORE Press Release | November 12, 2021 Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11 READ MORE Press Release | November 02, 2021 Vertex Reports Third-Quarter 2021 Financial Results READ MORE Pagination Current page 1 Page 2 Page 3 Next page Next
